Cycle Launches Sajazir as Treatment Option for Acute HAE Attacks

Cycle Launches Sajazir as Treatment Option for Acute HAE Attacks

307756

Cycle Launches Sajazir as Treatment Option for Acute HAE Attacks

Cycle Pharmaceuticals has launched Sajazir, an injectable form of icatibant, as a new treatment option for acute attacks of hereditary angioedema (HAE) in adults. Patients who use Sajazir can take advantage of Cycle Vita, the company’s recently created rare disease product support hub. Icatibant, also sold as Firazyr, by Takeda Pharmaceuticals, is approved by the U.S. Food and Drug Administration (FDA) for treating HAE, which is estimated to affect more than 7,000 people in the United States. The…

You must be logged in to read/download the full post.